AC Immune backs alpha-synuclein despite recent setbacks
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
The Delta for Covid-19 vaccine efficacy
Pfizer/Biontech's and Astrazeneca’s Covid-19 vaccines come out strong in an analysis of thousands of UK cases of the Delta variant.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
Glaxo set to ask investors to keep the faith
The beleaguered big pharma is under huge pressure to change minds at Wednesday’s investor event.
Curevac’s credibility unravels along with its Covid-19 vaccine
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
